此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Impact of Lung Cancer Screening With Chest Scans Combined With Coaching on Smoking Cessation in Heavy Smokers

2026年10月16日 更新者:Philippe Khafagy、Hôpital Fribourgeois

Smoking Termination Outcomes With Pulmonary Low Dose Computed Tomography for Lung Cancer Screening (STOP-LungCancer)

Lung cancer is common and serious, but when detected early, the chances of recovery are significantly better. Tobacco use is the leading cause. To help people break free from smoking, the Fribourg Cantonal Hospital (HFR), the Center for Tobacco Prevention (CIPRET), and the Fribourg Cancer League are joining forces in the STOP-LungCancer study (Smoking Termination Outcomes with Pulmonary Low Dose Computed Tomography for Lung Cancer Screening).

What is the goal of this study? The investigators want to determine whether seeing and understanding images of the participants' own lungs helps participants quit smoking for good. Smoking cessation will be verified at 6 months using a breath test (measuring carbon monoxide), followed by a 2-year follow-up.

How does participation work? The study is open to 116 residents of the canton of Fribourg aged 50 to 79 who are heavy smokers and motivated to quit.

The program includes:

  1. Personalized support: 4 smoking cessation coaching sessions organized by CIPRET.
  2. Lung computed tomography (CT) scans: 3 exams spaced one year apart. This scan involves no needles or injections. The radiation dose is very low, about 0.6 millisieverts (mSv) per scan, and the associated risk is considered very low.
  3. A review of the images with a doctor: During dedicated consultations, a thoracic radiologist reviews the participant's own computed tomography (CT) scans with the participant to explain the condition of the lungs and heart.

What are the benefits? Participants receive both tailored support to quit smoking and close monitoring to detect any potential issues at a very early stage.

研究概览

研究类型

介入性

注册 (估计的)

116

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Canton of Fribourg
      • Fribourg、Canton of Fribourg、瑞士、1700
        • Fribourg Cantonal Hospital (HFR)
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

50年 至 79年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Residence in the canton of Fribourg
  • Willingness to quit smoking
  • Current smoker: > or = 20 packs years

Exclusion Criteria:

  • Previous diagnosis of cancer
  • Major medical problems (Eastern Cooperative Oncology Group, ECOG ≥ 2)
  • Chest computed tomography (CT) scan in the last 12 months
  • Hemoptysis or unintentional weight loss > 7 kilograms (kg) in the last year
  • Pregnancy
  • Refusal to be informed of incidental findings of medical importance

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Combined Low-Dose Computed Tomography Screening and Smoking Cessation Coaching

Single-arm experimental cohort of heavy smokers undergoing an integrated lung cancer screening and smoking cessation pathway. All enrolled participants receive the combined intervention strategy, which pairs personalized chest computed tomography (CT) imaging results with dedicated specialist counseling and structured behavioral smoking cessation support. This arm aims to evaluate how visual radiological feedback combined with tobacco cessation counseling impacts long-term smoking abstinence rates.

Face-to-face physician consultations where a thoracic radiologist reviews the participant's own computed tomography (CT) scans with the participant to explain lung and cardiovascular health, creating a visual "teachable moment".

Four structured behavioral counseling sessions delivered by certified tobacco cessation experts of the Center for Tobacco Prevention (CIPRET), personalized to support long-term abstinence.

其他名称:
  • Smoking Cessation Counselling

Low-dose chest computed tomography (LDCT) scans without intravenous contrast at baseline, 12 months, and 24 months, and additional follow-up LDCT when indicated by the screening result (Lung Computed Tomography Screening Reporting and Data System [Lung-RADS] category 3).

其他名称:
  • lung cancer screening (LCS)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
6-Month Smoking Abstinence Rate
大体时间:6 months after the first chest computed tomography (CT)

Proportion of participants who achieve smoking abstinence at 6 months after the first chest computed tomography (CT). Abstinence is self-reported and objectively validated using exhaled carbon monoxide (CO) measurement.

6 months after the first chest computed tomography (CT)

次要结果测量

结果测量
措施说明
大体时间
Smoking Abstinence Rate at 12 Months
大体时间:12 months after the first chest computed tomography

Proportion of participants reporting smoking abstinence at the 12-month visit, confirmed by exhaled carbon monoxide (CO) measurement.

12 months after the first chest computed tomography
Smoking Abstinence Rate at 24 Months
大体时间:24 months after the first chest computed tomography

Proportion of participants reporting smoking abstinence at the 24-month visit, confirmed by exhaled carbon monoxide (CO) measurement.

24 months after the first chest computed tomography
Detection Rate of Lung Nodules and Lung Cancer
大体时间:Baseline, 12 months, and 24 months

Proportion of participants with positive low-dose computed tomography (LDCT) findings requiring further diagnostic follow-up or tissue biopsy, categorized according to the standardized Lung Computed Tomography Screening Reporting and Data System (Lung-RADS) assessment categories.

Baseline, 12 months, and 24 months
Prevalence of Relevant Incidental Findings on Chest Computed Tomography
大体时间:Baseline, 12 months, and 24 months

Proportion of relevant non-lung-nodule incidental findings detected on low-dose chest computed tomography, such as smoking-related lung disease, cardiac abnormalities and other findings unrelated to smoking.

Baseline, 12 months, and 24 months
Factors Potentially Influencing Smoking Cessation Success
大体时间:At baseline

Exploratory analysis evaluating demographics such as age, sex, place of residence, socioeconomical class, and other factors such as smoking-related lung disease, and cardiac abnormalities. These analyses are exploratory in nature and are intended to generate hypotheses for future studies. No definitive causal inference will be drawn from these analyses.

At baseline

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Philippe Khafagy, MD、Hôpital Fribourgeois
  • 首席研究员:Jon Lutz, MD、Hôpital Fribourgeois

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2027年1月1日

初级完成 (估计的)

2031年6月30日

研究完成 (估计的)

2032年12月31日

研究注册日期

首次提交

2026年9月30日

首先提交符合 QC 标准的

2026年9月30日

首次发布 (实际的)

2026年10月6日

研究记录更新

最后更新发布 (实际的)

2026年10月21日

上次提交的符合 QC 标准的更新

2026年10月16日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual participant data will not be made publicly available to protect participant privacy and maintain confidentiality in accordance with Swiss regulatory requirements (Human Research Act and Federal Act on Data Protection). Aggregated data and primary results will be available in peer-reviewed scientific publications.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅